At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,346 enrolled
Drug / intervention
Ozanimod +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
In Brief
A Phase 3 clinical trial evaluating Ozanimod, Interferon beta-1a, and 2 other interventions for Multiple Sclerosis. Completed, enrolled 1,346 participants across 224 sites in 25 countries.
Detailed Summary
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesBelarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, Georgia, Germany, Hungary, Latvia, Lithuania, Moldova, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartDec 2014
Primary CompletionDec 2016
TodayJul 2026
First PostedNov 19, 2014
Enrollment StartDec 3, 2014
Primary CompletionDec 22, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.6 years ago
Interventions
Ozanimoddrug
Capsules for oral administration once a day
Interferon beta-1adrug
Administered by intramuscular injection once a week
Placebo to ozanimoddrug
Matching placebo capsules administered orally once a day
Placebo to interferon beta-1adrug
Placebo intramuscular injection once a week